UK's NICE gives early no to expanded use of AstraZeneca's Lynparza

In a draft decision, a committee for the U.K.'s cost watchdog recommended not providing coverage for expanded use of the PARP inhibitor in ovarian cancer.

By Andrew Dunn • Nov. 9, 2018

Earnings reveal pharma's mixed feelings on Trump drug pricing proposal

A plan that would shake up how CMS pays for Medicare Part B drugs could leave the bottom lines of major players like Roche, Amgen and Bristol-Myers exposed, according to analysts.​

By Jacob Bell • Nov. 7, 2018

Explore the Trendline➔

Drug pricing

President Trump’s efforts to install a most-favored nation pricing policy present new risks for an industry already adjusting to Medicare price negotiations.

By BioPharma Dive staff

5 election takeaways for pharma

Democrats took back the House on Tuesday, raising the prospect of more scrutiny on drug pricing. Experts, however, don't expect a major deal with President Trump.

By Ned Pagliarulo • Nov. 7, 2018

Come January, will pharma pricing pledges hold?

Pfizer CEO Ian Read indicated this week that the pharma, which rolled back some price hikes in July, would return to "business as normal" next year. 

By Ned Pagliarulo • Oct. 31, 2018

Amgen cuts US Repatha price 60% amid market pressure

While effective, the cholesterol drug's $14,520 list price has been a tough pill to swallow for payers. Now, Amgen will cut the price to $5,850.

By Ned Pagliarulo , Jacob Bell • Updated Oct. 24, 2018

DTC's big issues: Trump, cancer drugs and the First Amendment

Direct-to-consumer drug advertising, while always controversial, looks set to become a battleground yet again.

By Ned Pagliarulo , Jacob Bell , Andrew Dunn • Oct. 24, 2018

Minnesota takes aim at Sanofi, Novo, Lilly for insulin prices

A lawsuit filed Tuesday claims that, rather than protect patient access, the companies jacked up insulin prices in order to offer greater rebates to PBMs.

By Jacob Bell • Oct. 17, 2018

J&J sees 'evolution in pricing, not a revolution' in 2019

"I think we just need to be careful; things such as list price alone [are] not the full extent of the information," said J&J's pharma unit chief on a Tuesday call.

By Jacob Bell • Oct. 16, 2018

5 questions on the Trump admin's bid to mandate prices in drug ads

Pharma, which spends billions each year to advertise its products on television, is expected to fiercely oppose the proposal.

By Ned Pagliarulo , Andrew Dunn • Oct. 16, 2018

Confronting pharma, Trump admin seeks price disclosure in drug ads

HHS chief Alex Azar announced the much-anticipated proposal Monday, dismissing a new pledge from trade lobby PhRMA as insufficient.

By Ned Pagliarulo , Andrew Dunn • Updated Oct. 15, 2018

Under pressure, drugmakers give an inch on DTC drug ads

Members of the trade group PhRMA will soon point consumers to drug cost information in direct-to-consumer TV ads, but won't go so far as to include prices upfront.

By Ned Pagliarulo • Updated Oct. 15, 2018

Gilenya beats Copaxone head-to-head at higher dose, study finds

The multiple sclerosis drugs are top-sellers for their respective makers, Novartis and Teva. Yet a Phase 3b trial showed an efficacy edge for Gilenya.

By Andrew Dunn • Oct. 11, 2018

Price increases on top drugs drove majority of recent growth, analysis finds

Over the past three years, roughly 60% of the growth in U.S. sales for four dozen top-selling drugs came via price increases, according to numbers crunched by investment firm Leerink.

By Ned Pagliarulo • Oct. 10, 2018